Reuters logo
BRIEF-FDA gives "orphan drug" status to Idera's skin cancer drug
June 22, 2017 / 8:44 PM / 3 months ago

BRIEF-FDA gives "orphan drug" status to Idera's skin cancer drug

June 22 (Reuters) - Idera Pharmaceuticals Inc-

* Idera announces FDA orphan drug designation for IMO-2125 for the treatment of melanoma

* Idera Pharmaceuticals Inc - expects to complete enrollment of phase 2 multicenter trial in h2 2017, overall response rate data available in q1 of 2018

* Idera Pharmaceuticals - company recently initiated a trial of imo-2125 monotherapy in refractory solid tumors, including pd-1 refractory melanoma

* Idera Pharmaceuticals - enrolling second arm in phase 1/2 clinical trial in patients with pd-1 refractory melanoma to study imo-2125 and pembrolizumab Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below